How We Explain IVF Success Rates
Reviewing IVF outcome statistics is a reasonable step when you are comparing clinics. A published average still doesn’t define your individual prognosis. Age, ovarian reserve, sperm findings, uterine factors, and previous cycle history all change the picture.
This page explains the definitions a clinic should provide so that a published figure can be read in context rather than as a promise. Assoc. Prof. Dr. Senai Aksoy reviews the page’s clinical methodology.
Table of Contents
- What a Published Success Rate Must Show
- How Success Rates Are Compared
- The Impact of Age on Your Pregnancy Chances
- Treatment Add-ons and Success-Rate Interpretation
What a Published Success Rate Must Show
Short Answer:
A percentage is not interpretable until the endpoint, denominator, patient group, treatment type, and reporting period are stated.
A positive β-hCG is an early blood-test marker of pregnancy. It is not the same endpoint as a clinical pregnancy confirmed by ultrasound, an ongoing pregnancy, or a live birth. A β-hCG positivity rate per embryo transfer will therefore answer a different question from live birth per egg collection or cumulative live birth per treatment started.
Before relying on a clinic figure, ask for the cohort dates, number of patients and cycles, age bands, use of own or donor eggs, fresh or frozen transfer status, PGT use, cancelled cycles, and a confidence or reliability range. Without those details, the figure should not be used to rank clinics or predict an individual outcome.
How Success Rates Are Compared — and Why They Often Aren’t Comparable
Short Answer:
A “success rate” only means something once you know exactly what’s being measured and against which denominator. Figures using different endpoints — per aspiration, per transfer, per started cycle — are not directly comparable, even when the percentages look similar.
A published “success rate” only tells you something once you know what’s actually being measured. Clinics and countries don’t all report the same endpoint: some use β-hCG positivity per embryo transfer, others clinical pregnancy per aspiration, others cumulative live birth per started cycle. A freeze-all protocol changes the timing of transfer, and PGT-selected transfers represent a selected subset of embryos. Compare two such figures without knowing which definition and patient pathway sits behind each one, and the comparison stops meaning much.
The scale of that spread is visible in the ESHRE European IVF-Monitoring (EIM) Consortium’s 2020 data, published in 2025 from 1,440 clinics across 41 European countries: clinical pregnancy rate per aspiration was 22.1% for IVF (rising to 26.4% once freeze-all cycles were excluded), while FET clinical pregnancy rate per thaw was 34.9% (ESHRE’s European IVF-Monitoring Consortium, 2025). These figures illustrate how the denominator and treatment pathway change the reported percentage; they are not a clinic ranking.
The HFEA explains that UK clinic figures are calculated consistently, but it also cautions that individual clinic rates cannot predict whether a particular patient will have a baby. Figures from an overseas clinic should not be compared with HFEA data unless the endpoint, denominator, cohort, and patient mix genuinely match.
What that number is actually counting matters: a positive pregnancy test, a gestational sac on ultrasound, or a live birth? At what age, and per embryo transfer or per patient who started treatment? Does it include frozen transfers, PGT-tested embryos, or only patients who already had a favourable prognosis? A percentage on its own, without that context, tells you more about how it was presented than about what actually happened.
A polished figure can conceal selection. For example, a clinical pregnancy rate calculated among younger patients who reached blastocyst transfer should not be presented to an older patient as her own chance if cancelled cycles or later pregnancy losses are outside the denominator. The clinically relevant question is the chance of a live birth over a defined treatment period for a comparable patient group, with uncertainty made visible.
The Impact of Age on Your Pregnancy Chances
Short Answer:
Age is an important prognostic factor in IVF outcomes, but it does not act alone. The cause of infertility, ovarian response, sperm factors, embryo availability, uterine factors, and previous treatment history also affect the interpretation.
The HFEA’s 2024 UK treatment figures show that birth rates per embryo transferred vary substantially by age. Those national UK figures describe treatment in HFEA-licensed clinics; they are not a benchmark that can be copied onto a Turkish clinic or used as a personal forecast.
Treatment Add-ons and Success-Rate Interpretation
Short Answer:
Laboratory technology or a treatment add-on should not be assumed to improve the chance of a live birth simply because it is available.
Time-lapse incubation can provide additional embryo-development information while embryos remain in a controlled incubator. Whether a technology changes a patient-important endpoint such as live birth must be assessed separately from its laboratory convenience or observational detail.
Preimplantation Genetic Testing (PGT-A)
PGT-A tests biopsied embryo cells for chromosome-number findings; it does not guarantee that an embryo is chromosomally normal or that treatment will result in a healthy birth. The HFEA currently rates PGT-A red for improving the chance of having a baby for most fertility patients, while separately assessing miscarriage outcomes. Its possible role should be discussed for the individual case rather than presented as a universal success-rate enhancer.
Frequently Asked Questions (FAQ)
It’s natural to have plenty of questions before starting IVF treatment. Here are answers to some of the ones we hear most often.
How many IVF attempts might be needed?
There is no single number that applies to everyone. A useful estimate needs age, diagnosis, ovarian response, embryo availability, treatment history, and a clearly defined outcome such as cumulative live birth per treatment started.
Does one unsuccessful embryo transfer predict future failure?
No. One unsuccessful transfer does not by itself establish recurrent implantation failure or identify a cause. The next assessment depends on embryo, uterine, sperm, treatment, and clinical-history factors; unproven tests or add-ons should not be assumed to improve the outcome.
Can fresh and frozen embryo transfer rates be compared directly?
Not reliably without matching the patient group, embryo stage, age, endpoint, and denominator. Frozen-transfer figures may reflect selection at several earlier steps, so a higher per-transfer percentage does not prove that freezing itself caused a better outcome.
Can I directly compare your success rate with another clinic's published rate?
Not reliably, unless both figures use the same endpoint, denominator, cohort period, age group, treatment type, and inclusion rules. A clinic should also show sample size and an uncertainty or reliability range before its figure is used for comparison.
Obtaining a Personalised Evaluation
Do not rely on a clinic percentage as a personal prognosis.
An individual assessment may consider age, diagnosis, previous treatment, ovarian reserve tests, ultrasound findings, semen analysis, and relevant medical records. Even then, an estimate remains uncertain and should state which outcome and treatment period it refers to.
Medical Disclaimer and Legal Notice
Last medical review: 15 August 2026. This review includes the updated methodology, UK comparison context, and treatment add-on wording.
The information on this page is educational and does not predict an individual chance of pregnancy or live birth. IVF outcomes vary with medical history and treatment details. It does not replace assessment by a qualified fertility specialist.
Sources
- Human Fertilisation and Embryology Authority. Choose a fertility clinic: understanding and comparing clinic data.
- Human Fertilisation and Embryology Authority. Fertility treatment 2024: trends and figures.
- Human Fertilisation and Embryology Authority. Pre-implantation genetic testing for aneuploidy (PGT-A).
- European IVF-Monitoring Consortium for ESHRE. ART in Europe, 2020: results generated from European registries.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
